Coherus Reaches Settlement With AbbVie Securing Rights To Commercialize CHS-1420

Coherus BioSciences Inc. (CHRS) said it has executed settlement agreements with AbbVie Inc. that grant Coherus global, non-exclusive license rights under AbbVie's intellectual property to commercialize CHS-1420, Coherus' proposed adalimumab (HUMIRA) biosimilar.

The global settlements resolve all pending disputes between the parties related to Coherus' adalimumab biosimilar. Under the U.S. settlement, Coherus' license period in the U.S. commences on December 15, 2023. Coherus will pay royalties to AbbVie. Financial terms are not disclosed.

CHS-1420 is among a number of significant biosimilar candidates in Coherus' pipeline of high-value treatments for patients in need, which include the company's biosimilar candidates directed to Enbrel, Lucentis and Eylea.

The company is currently preparing its biologics license application for CHS-1420 for submission to the U.S. Food and Drug Administration, with anticipated filing in late 2019.

Upon the expected U.S. market launch of CHS-1420 in late 2023, the company believes it will be well-positioned to effectively leverage the commercial infrastructure it has already deployed for its recent U.S. launch of UDENYCA (pegfilgrastim-cbqv). Coherus continues to evaluate options and potential strategies for ex-U.S. commercialization of CHS-1420.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Retailers Macy's, Inc. (M) and Dollar General Corp. (DG) reported on Thursday that net profits for the first quarter declined from last year, with Macy's topping estimates, while Dollar General missed it. Net sales at both retailers missed expectations. Both Macy's and Dollar General also slashed their guidance for the full-year 2023. The U.S. Food and Drug Administration has warned certain retailers against unauthorized sales of popular disposable e-cigarettes, mainly various types of Puff and Hyde brand e-cigarettes. Under the retailer inspection blitz, warning letters have been issued to 30 retailers, including one distributor, for illegally selling such products. All products cited in the warning letters are disposable Tillamook County Creamery Association is recalling a limited quantity of family-size 1.5qt cartons of Tillamook Waffle Cone Swirl ice cream due to undeclared wheat and soy, known allergens, the U.S. Food and Drug Administration said. The Tillamook Waffle Cone Swirl ice cream was mistakenly packaged in a Tillamook Chocolate Peanut Butter ice cream carton.
Follow RTT